Eversense Changes the Lives of Those with Diabetes
March 18, 2019
SAY GOODBYE TO WEEKLY SENSOR SELF-INSERTIONS WITH EVERSENSE
Last month, we sat down with Laura Kronen, who shared her experience with managing diabetes. She’s back to give us an update on life with Eversense. Engineered for long-lasting accuracy and ease of use, the Eversense Long-Term Continuous Glucose Monitoring (CGM) System offers advantages over traditional CGM.
As a diabetic for more than 25 years, the Eversense is changing the game for people living with diabetes – including Laura. This particular device is the first and only long-term CGM that lasts up to 90 days and is placed in your arm. That means no weekly sensor self-insertions.
In addition, it quickly detects glucose highs and lows. In clinical studies, the Eversense system detected 95% of hypoglycemic episodes (70 mg/dL) and 99% of hyperglycemic episodes (180 mg/dL) within 15 minutes.
It also features alerts you can see, feel, and hear. The system can be configured to provide three types of alerts: visual, auditory, and on-body vibe alerts, which can provide you with an additional safety advantage, even during sleep.
The best part? It’s discreet and flexible. The smart transmitter, with its low profile and flexibility to remove and reattach without wasting a sensor, enables a new level of discretion.
Stay tuned as Laura shares her life-changing experience!
Knowing the risk of being an OTC carrier and how to prepare for it with the UCD Genetic Testing Program, sponsored by Horizon Therapeutics and performed by Invitae.
Acromegaly is a slow-progressing disorder that occurs when the pituitary gland produces too much growth hormone.
Up next, stay tuned for a brand-new Behind the Mystery special — only on The Balancing Act.